ASCOLT
12 Jan 2018
Trial Summary
We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally.
Acronym:
ASCOLT
ACTRN/NCT /ethics:
NCT00565708
Scientific title:
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
Sponsor / Cooperative group:
–
Trial & Patient Characteristics
| Cancer Type | Bowel |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18+ years |
| Sex | Both |
| Tumour Stream | Bowel |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-12-01 |
| Anticipated End Date | 2026-01-06 |
Participating Hospitals
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Professor Tim Price |
| Recruitment Status | Recruiting |